CAMK2B and atrial fibrillation: Mice with reduced PI3K/Akt activity were found to be more susceptible to AF (105) and had increased ROS production which promoted CaMK2 activation in mice treated with ibrutinib, a likely contributor to atrial fibrosis, remodelling and AF (106).